Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | April 23, 2010 | April 23, 2010 |
| MiniMed Group, Inc.MMED · Entity 3758 | Director | October 09, 2026 | October 13, 2026 |
| Outset Medical, Inc.OM · Entity 7026 | Director | June 04, 2026 | June 05, 2026 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | January 04, 2021 | January 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date April 23, 2010 · Filed April 23, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2010-04-23 transaction · row 19
19 source rows · reconciled sequenceRow 1 · 2010-04-23 · Exercise / conversion · Acquired 4,250 · Balance 4,250 Row 2 · 2010-04-23 · Sale · Disposed 200 · Balance 4,050 Row 3 · 2010-04-23 · Sale · Disposed 300 · Balance 3,750 Row 4 · 2010-04-23 · Sale · Disposed 100 · Balance 3,650 Row 5 · 2010-04-23 · Sale · Disposed 400 · Balance 3,250 Row 6 · 2010-04-23 · Sale · Disposed 200 · Balance 3,050 Row 7 · 2010-04-23 · Sale · Disposed 100 · Balance 2,950 Row 8 · 2010-04-23 · Sale · Disposed 200 · Balance 2,750 Row 9 · 2010-04-23 · Sale · Disposed 100 · Balance 2,650 Row 10 · 2010-04-23 · Sale · Disposed 100 · Balance 2,550 Row 11 · 2010-04-23 · Sale · Disposed 300 · Balance 2,250 Row 12 · 2010-04-23 · Sale · Disposed 100 · Balance 2,150 Row 13 · 2010-04-23 · Sale · Disposed 300 · Balance 1,850 Row 14 · 2010-04-23 · Sale · Disposed 100 · Balance 1,750 Row 15 · 2010-04-23 · Sale · Disposed 200 · Balance 1,550 Row 16 · 2010-04-23 · Sale · Disposed 6 · Balance 1,544 Row 17 · 2010-04-23 · Sale · Disposed 104 · Balance 1,440 Row 18 · 2010-04-23 · Sale · Disposed 90 · Balance 1,350 Row 19 · 2010-04-23 · Sale · Disposed 1,350 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.39 · Expires 2019-04-23 | Direct | 0 |
Reported balance
After 2010-04-23 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2010-04-23 · Exercise / conversion · Disposed 4,250 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
MiniMed Group, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,684 |
Reported balance
After 2026-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 11,795 · Balance 25,684 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUS. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUS.
Outset Medical, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,585 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,667 · Balance 24,585 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
| Common StockSEC Table I · non-derivative | IndirectGrossman Fam Trust | 12,845 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,845 |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
ViewRay, Inc.
Report date January 04, 2021 · Filed January 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The D. Keith and Hallie H. Grossman Family Living Trust | 100,855 |
Reported balance
After 2021-01-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 7,800 · Balance 100,855 F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 4, 2031 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2021 such that 100% of the DSUs will be vested on December 31, 2021, subject to the Reporting Person remaining a service provider through each such vesting date. F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $50,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 4, 2031 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2021 such that 100% of the DSUs will be vested on December 31, 2021, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $50,000.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 228,552 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Disposed 14,137 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 14,137 shares held by the Reporting Person, (i) 11,669 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 2,468 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2023-10-23 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Other · Disposed 18,987 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Other · Disposed 30,000 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, out of the total of 14,137 shares held by the Reporting Person, (i) 11,669 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 2,468 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 22:12 UTC | MiniMed Group, Inc. MMED · Entity 3758 | GrantCommon Stock | 11,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001218702-26-000003 · wk-form4_1791929517.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,684 F1 · shares: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2 · balance_after: Includes shares of common stock to be issued in connection with the vesting of one or more RSUS. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:08 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 10,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-26-000031 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,585 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:31 UTC | MiniMed Group, Inc. MMED · Entity 3758 | GrantCommon Stock | 13,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-016856 · wk-form4_1773261072.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,889 F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date. F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:23 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 8,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-25-000054 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,918 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders F2 · balance_after: These numbers have been adjusted to reflect the 1-for-15 reverse stock split the Issuer effected on March 20, 2025 (the "Reverse Stock Split"). Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 228,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050467 · ownership.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| March 11, 2025 Filed Mar 11, 2025 18:42 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,641 | $5.78 | $9,484.98 |
DisclosureSEC source: 0001444380-25-000045 · wk-form4_1741732962.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,552 F1 · balance_after: Includes 19,169 restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:23 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionSeries A Non-Voting Convertible Preferred · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001484612-25-000035 · edgardoc.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 0 Underlying: Preferred Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:23 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 187,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001484612-25-000035 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 192,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its Meeting of Stockholders, held on March 5, 2025, after which each share of Preferred Stock automatically converted into 250 shares of Common Stock on March 10, 2025. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:23 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantSeries A Non-Voting Convertible Preferred · Derivative | 750 | $200.00 Strike: $0.00 | $150,000.00 |
DisclosureSEC source: 0001484612-25-000035 · edgardoc.xml · derivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 750 Underlying: Preferred Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its March 5, 2025 Meeting of Stockholders (the "Conversion Proposal"). The Issuer's stockholders approved the Conversion Proposal and each share of Preferred Stock will automatically convert into 250 shares of Common Stock, subject to certain limitations. The Preferred Stock has no expiration date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 17:26 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,017 | $5.72 | $5,817.24 |
DisclosureSEC source: 0001444380-25-000026 · wk-form4_1741127153.xml · nonDerivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,193 F2 · balance_after: Includes 24,408 restricted stock units. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:26 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,071 | $5.72 | $6,126.12 |
DisclosureSEC source: 0001444380-25-000026 · wk-form4_1741127153.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,210 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:26 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001444380-25-000026 · wk-form4_1741127153.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,281 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on March 03, 2022 that were subject to a performance-based vesting condition. The Compensation Committee of the Issuer certified the achievement of the second milestone vesting condition upon which a portion of the PSUs vested. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 16:04 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 928 | $4.26 | $3,953.28 |
DisclosureSEC source: 0001444380-24-000012 · wk-form4_1733346249.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,531 F1 · balance_after: Includes 28,575 restricted stock units. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:02 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,020 | $5.55 | $5,661.00 |
DisclosureSEC source: 0001610717-24-000462 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,459 F1 · balance_after: Includes 32,741 restricted stock units. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 38,117 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · derivative · entry 7 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,117 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. F3 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,186 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · derivative · entry 6 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 Underlying: Common Stock · 31,186 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. F3 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 11,887 | $3.74 | $44,468.08 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · nonDerivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,035 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $3.66-$3.83. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 38,117 | $1.11 | $42,309.87 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · nonDerivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 26,230 | $3.80 | $99,765.81 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,805 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $3.66-$3.83. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:57 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 31,186 | $1.11 | $34,616.46 |
DisclosureSEC source: 0001484612-24-000057 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:06 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,134 | $9.33 | $10,580.22 |
DisclosureSEC source: 0001610717-24-000283 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,479 F1 · balance_after: Includes 36,907 restricted stock units. Read SEC document |
| May 29, 2024 Filed May 29, 2024 23:06 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-24-000051 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,849 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:52 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 19,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000260 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,613 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 41,073 RSUs. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 16:08 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 3,986 | $13.12 | $52,296.32 |
DisclosureSEC source: 0001610717-24-000207 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,444 F1 · balance_after: Includes 21,904 restricted stock units. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 16:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,184 | $14.99 | $32,738.16 |
DisclosureSEC source: 0001610717-24-000159 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,430 F1 · balance_after: Includes 30,002 restricted stock units. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,597 | $14.51 | $23,172.47 |
DisclosureSEC source: 0001610717-24-000139 · form4.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,614 F2 · balance_after: Includes 35,240 restricted stock units. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:27 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000139 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,211 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on March 3, 2022 that were subject to a performance-based vesting condition. The Compensation Committee of the Issuer certified the achievement of the first milestone vesting condition upon which a portion of the PSUs vested. F2 · balance_after: Includes 35,240 restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 16:18 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,403 | $14.22 | $19,950.66 |
DisclosureSEC source: 0001610717-24-000127 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,461 F1 · balance_after: Includes 35,240 restricted stock units. Read SEC document |
| December 03, 2023 Filed Dec 5, 2023 17:15 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,056 | $18.82 | $38,693.92 |
DisclosureSEC source: 0001610717-23-000374 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,864 F1 · balance_after: Includes 39,407 restricted stock units. Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 16:34 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 6,012 | $15.75 | $94,689.00 |
DisclosureSEC source: 0001610717-23-000317 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,920 F1 · balance_after: Includes 43,573 restricted stock units. Read SEC document |
| September 03, 2023 Filed Sep 6, 2023 17:49 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,193 | $20.39 | $44,715.27 |
DisclosureSEC source: 0001610717-23-000255 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,932 F1 · balance_after: Includes 54,993 restricted stock units. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 16:35 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 6,013 | $24.16 | $145,274.08 |
DisclosureSEC source: 0001610717-23-000218 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,125 F1 · balance_after: Includes 59,159 restricted stock units. Read SEC document |
| June 03, 2023 Filed Jun 6, 2023 16:41 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,193 | $28.27 | $61,996.11 |
DisclosureSEC source: 0001610717-23-000096 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,138 F1 · balance_after: Includes 70,580 restricted stock units. Read SEC document |
| May 31, 2023 Filed May 31, 2023 22:59 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 7,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-23-000043 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,849 F1 · kind: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 17:57 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 22,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000032 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,331 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/2 of the RSUs will vest on each three month anniversary following April 24, 2024, such that all RSUs will be fully vested by the six month anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 74,746 RSUs. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 16:08 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,263 | $35.66 | $152,018.58 |
DisclosureSEC source: 0001610717-23-000005 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,490 F1 · balance_after: Includes 51,905 restricted stock units. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 16:18 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,757 | $30.19 | $83,233.83 |
DisclosureSEC source: 0001567619-23-005046 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,753 F1 · balance_after: Includes 60,003 restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 8,798 | $34.43 | $302,915.14 |
DisclosureSEC source: 0001567619-23-004583 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,510 F1 · balance_after: Includes 65,241 restricted stock units. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 20:21 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 6,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-22-000045 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,168 F1 · kind: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 17:48 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008447 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,308 F1 · balance_after: Includes 81,911 restricted stock units. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 20:31 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 77,734 | $67.08 | $5,214,396.72 |
DisclosureSEC source: 0001567619-22-007617 · doc1.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,571 F2 · balance_after: Includes 90,009 restricted stock units. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 20:31 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 147,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007617 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,305 F1 · shares: On March 19, 2019, the Reporting Person was granted Performance Stock Units, the vesting of which was subject to the achievement of certain performance criteria. On March 24, 2022, the Board of Directors determined that 147,644 shares of Common Stock were earned as result of the achievement of such performance criteria. F2 · balance_after: Includes 90,009 restricted stock units. Read SEC document |
| March 19, 2022 Filed Mar 21, 2022 20:57 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,875 | $70.61 | $344,223.75 |
DisclosureSEC source: 0001567619-22-007328 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,661 F1 · balance_after: Includes 90,009 restricted stock units. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 20:05 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,754 | $64.09 | $176,503.86 |
DisclosureSEC source: 0001567619-22-007007 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,536 F1 · balance_after: Includes 99,269 restricted stock units. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 21:35 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 3,200 | $63.59 | $203,488.00 |
DisclosureSEC source: 0001567619-22-006590 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,290 F1 · balance_after: Includes 104,507 restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:47 UTC | NEVRO CORP NVRO · Entity 12422 | GrantPerformance-based Restricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006484 · doc1.xml · derivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2025-03-03 F3 · derivative.exercise_price: Represents performance-based restricted stock units ("PSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock. The PSUs vest upon issuer's common stock achieving a specified price per share. F3 · derivative.exercise_date: Represents performance-based restricted stock units ("PSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock. The PSUs vest upon issuer's common stock achieving a specified price per share. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:47 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006484 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,090 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on February 28, 2023 and the remainder will vest quarterly thereafter, such that all shares will be fully vested by the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 104,507 restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 21:24 UTC Amendment | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006589 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,090 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on February 28, 2023 and the remainder will vest quarterly thereafter, such that all shares will be fully vested by the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F3 · acquired: Due to a scrivener's error, the Form 4 previously filed for the reporting person on March 7, 2022 reported the reporting person's grant of RSUs as a disposition in Table I Box 4. The transaction is an acquisition and should have been marked "A" in Table I Box 4. F2 · balance_after: Includes 104,507 restricted stock units. Read SEC document |
| December 19, 2021 Filed Dec 21, 2021 19:48 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,874 | $85.81 | $418,237.94 |
DisclosureSEC source: 0001567619-21-022428 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,090 F1 · balance_after: Includes 54,507 restricted stock units. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:44 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $47.92 | $62,104.32 |
DisclosureSEC source: 0001484612-21-000091 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 5,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.